Silexion Therapeutics Corp Revenue
Biotechnology Research • 
Modiin-Maccabim-Reut, Center District, Israel • 11-20 Employees
Silexion Therapeutics Corp revenue & valuation
| Annual revenue | $1,283,325 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $4,200,000 |
| Total funding | $12,800,000 |
Key Contacts at Silexion Therapeutics Corp
Dikla Chen
Director Of Finance
Nira Nuriely
Human Resources Director
Meni Sofiof
Director Of Finance
Shiri Pur-Levy
Director Of Quality Assurance
Company overview
| Headquarters | 2 Hamayan st, Modin, 7177871, IL |
| Website | |
| NAICS | 541714 |
| Employees | 11-20 |
| Socials |
Silexion Therapeutics Corp Email Formats
Silexion Therapeutics Corp uses 4 email formats. The most common is {first name} (e.g., john@silexion.com), used 38.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name} | john@silexion.com | 38.1% |
{first initial} | j@silexion.com | 33.3% |
{first name}{last name} | johndoe@silexion.com | 19% |
{first initial}{last name} | jdoe@silexion.com | 9.5% |
About Silexion Therapeutics Corp
Silexion Therapeutics is a pioneering clinical-stage oncology-focused biotechnology company engaged in discovering and developing proprietary treatments for KRAS-driven cancers. The company’s platform technology is addressing difficult-to-treat solid tumors. Silexion’s lead product candidate, SIL-204, consists of locally administered small interfering RNAs, or siRNA, in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients combined with standard-of-care chemotherapy. SIL-204 is a siRNA product candidate following Phase 1 and Phase 2 clinical trials with Silexion’s first-generation siG12D-LODER, also referred to as LODER™. Results from the LODER™ Phase 2 clinical trial showed a trend for differences between treatment groups with the LODER arm suggesting an overall survival advantage of 9.3 months. Silexion commitment to Pushing the boundaries of therapeutic advancements in the field of oncology is focused on its second-generation microparticle delivery system, SIL-204 a newly formulated product that will improve clinical efficacy. Silexion plans to conduct a Phase 2/3 trial of SIL-204 in locally advanced pancreatic cancer patients that harbor the KRAS G12D and G12V mutations. Silexion Therapeutics Ltd. is headquartered in Israel and partnered with well known GMP compliant siRNA facility, LGC Axolabs group located in Petaluma California, and worldwide experts extended-release formulation facility, EVONIK Corporation located in Birmingham, Alabama to upscale manufacturing.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Silexion Therapeutics Corp has 8 employees across 5 departments.
Departments
Number of employees
Funding Data
Explore Silexion Therapeutics Corp's funding history, including investment rounds, total capital raised, and key backers.
Silexion Therapeutics Corp Tech Stack
Discover the technologies and tools that power Silexion Therapeutics Corp's digital infrastructure, from frameworks to analytics platforms.
WordPress plugins
WordPress themes
Page builders
JavaScript libraries
CDN
JavaScript libraries
Miscellaneous
Security
Programming languages
Blogs
Analytics
Germany
United States
United Kingdom
Frequently asked questions
4.8
40,000 users
